| Literature DB >> 35759136 |
Kakeru Chino1, Naotaka Izuo1, Hiroshi Noike1, Kyosuke Uno1,2, Tomoharu Kuboyama3, Chihiro Tohda4, Shin-Ichi Muramatsu5,6, Atsumi Nitta7.
Abstract
Alzheimer's disease (AD) is a type of dementia characterized by the deposition of amyloid β, a causative protein of AD, in the brain. Shati/Nat8l, identified as a psychiatric disease related molecule, is a responsive enzyme of N-acetylaspartate (NAA) synthesis. In the hippocampi of AD patients and model mice, the NAA content and Shati/Nat8l expression were reported to be reduced. Having recently clarified the involvement of Shati/Nat8l in cognitive function, we examined the recovery effect of the hippocampal overexpression of Shati/Nat8l in AD model mice (5XFAD). Shati/Nat8l overexpression suppressed cognitive dysfunction without affecting the Aβ burden or number of NeuN-positive neurons. In addition, brain-derived neurotrophic factor mRNA was upregulated by Shati/Nat8l overexpression in 5XFAD mice. These results suggest that Shati/Nat8l overexpression prevents cognitive dysfunction in 5XFAD mice, indicating that Shati/Nat8l could be a therapeutic target for AD.Entities:
Keywords: AAV vector; Alzheimer’s disease; Amyloid β; BDNF; Cognitive dysfunction; Shati/Nat8l
Mesh:
Substances:
Year: 2022 PMID: 35759136 DOI: 10.1007/s11064-022-03649-2
Source DB: PubMed Journal: Neurochem Res ISSN: 0364-3190 Impact factor: 4.414